JPAD-Journal of Prevention of Alzheimers Disease

Article	Citations
Herpes zoster and dementia : more evidences for a causal link	712
Gene and genetic therapies in Alzheimer’s disease and other dementias	190
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort	154
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	130
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France	127
Lecanemab over a two-year duration: Key insights from a regional specialty medical center	101
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.	100
Long-term fasting insulin variability and cognitive function: Insights from the CARDIA study	98
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice	86
Prevention of dementia using mobile phone applications (PRODEMOS) – a health-economic cost-utility analysis in people aged 55–75 years with low socio-economic status	83
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data	74
Structural social factors modify the association between Alzheimer’s pathology and cognitive function	70
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use	64
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease	62
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings	51
Sleep complaints and genetic risk of Alzheimer’s disease in older women: associations with memory and tau deposition	51
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation	51
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217	48
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease	47
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status	43
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations	43
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment	41
Introduction to the Special Issue on the A4 Study	41
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese	39
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review	39

The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test	38
Content	37
Independent and Joint Associations of Socioeconomic Status and Lifestyle behaviors with Cognitive Impairment among Elderly Chinese Population	36
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6	35
A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care	35
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias	34
Informal care for people with dementia in Europe	34
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system	32
Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer’s disease	32
Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities	30
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease	29
Donanemab: Appropriate use recommendations	29
The Therapeutic Effects of Noninvasive Brain Stimulation Combined with Cognitive Training in Elders with Alzheimer's Disease or Amnesic Mild Cognitive Impairment	28
Disease-Modifying Antirheumatic Drugs and Dementia Prevention: A Systematic Review of Observational Evidence in Rheumatoid Arthritis	27
Editorial Board	27
Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions	27
Erratum to: Education as Risk Factor of Mild Cognitive Impairment: The Link to the Gut Microbiome	26
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease	26
Living arrangements and cognitive resilience in aging: unraveling distinct pathways through plasma biomarkers	26
Erratum to: Alzheimer's Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease	26
Are Population-Level Approaches to Dementia Risk Reduction Under-Researched? A Rapid Review of the Dementia Prevention Literature	26
Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Older Adults with Normal Cognition or Mild Cognitive Impairment	25
New-generation antidiabetic medications and dementia risk in older adults with type 2 diabetes: A retrospective cohort study	25
In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum	25
Treatments for Alzheimer’s and the declaration of Helsinki	25
Longitudinal Impacts of Precision Greenness on Alzheimer's Disease	24
The role of Tau, amyloid-β and neuroinflammation in the association between cognition and white matter hyperintensities in a southeast Asian cohort	24
Differential effects of soluble and plaque amyloid on late-life depression: The moderating role of tau pathology	24
Cardiovascular-kidney-metabolic syndrome and incidence of dementia among older adults	24
Preclinical detection of Alzheimer’s disease pathology using conceptual discrimination abilities	24
Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension	24
Multi-modal data analysis for early detection of alzheimer’s disease and related dementias	24
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?	23
What can artificial intelligence bring to Alzheimer’s disease clinical trials? A first perspective	23
Global Burden of Dementia Death from 1990 to 2019, with Projections to 2050: An Analysis of 2019 Global Burden of Disease Study	23
Programmed Death of Microglia in Alzheimer's Disease: Autophagy, Ferroptosis, and Pyroptosis	23
Association of Vascular Endothelial Growth Factor Levels with Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis	22
Late-life body mass index and amyloid interaction on cognitive decline in unimpaired older adults	22
Blood pressure and Alzheimer’s disease biomarkers in cognitively unimpaired adults: a multicenter study	22
The Causal Relationship between Genetically Predicted Biological Aging, Alzheimer's Disease and Cognitive Function: A Mendelian Randomisation Study	22
Trajectories of muscle strength and physical performance preceding dementia in older US and European populations	22
16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24–27, 2023: Posters	22
Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform	22
Income, diet, and cognitive function: observational analyses and candidate metabolomic pathways identified by Mendelian randomization	21
Adapting the spanish healthcare system for disease-modifying treatments in early-stage alzheimer’s disease	21
Adherence to an anti-inflammatory diet is associated with lower Alzheimer’s disease mortality: A modifiable risk factor in a national cohort	21
Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4	21
Hypolipidemics reduce the rate of Alzheimer's disease development and dementia progression: A cohort study linked with genetic and neuropathological analyses	20
Serum Tau-A and Tau-C Levels and Their Association with Cognitive Impairment and Dementia Progression in a Memory Clinic Derived Cohort	20
Erratum to: Digital Clock Drawing as an Alzheimer's Disease Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in Older Adults	20

Effectiveness of Physical Exercise on Alzheimer's disease. A Systematic Review	20
Corrigendum to “17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: Symposia, Oral Communications” [J Prev Alzheimers Dis 2025;12(1S):100043].	20
A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice	19
Clarifying what BP Predicts: Commentary on CSF Aβ42/40, p-tau181, and centiloid in unimpaired populations	19
Development of a Mobile-First Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies	19
Predicting cognitive decline: Comparative analysis of ANU-ADRI, CAIDE, CogDrisk, LIBRA, LIBRA2, UKBDRS and Lancet based dementia risk scores in the HUNT study	19
Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC	18
Reproductive Markers in Alzheimer's Disease Progression: The Framingham Heart Study	18
Modulatory Effect of Blood LDL Cholesterol on the Association between Cerebral Aβ and Tau Deposition in Older Adults	18
Amyloid pathology and modifiable risk factors in cognitive decline among cognitively unimpaired older adults	18
Association between MRI indicators of the glymphatic system and cognition in high-risk populations for Alzheimer's disease	18
Eligibility of men vs. women in Alzheimer’s trials: Inclusive vs. representative	18
Lipid-lowering regimens in Alzheimer’s disease dementia: small effects with potential long-term benefit	18
Association of life’s simple 7 with cognitive function in a multi-ethnic cohort	18
Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EM	17
Associations of early-onset coronary heart disease and genetic susceptibility with incident dementia and white matter hyperintensity: A prospective cohort study	17
Current Themes and Controversies in the Alzheimer's Disease Field: Looking Ahead to the CTAD Meeting in San Francisco, November 29–December 2 2022	17
Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults	17
Identifying the optimal combinations of modifiable dementia risk factors to target in multidomain intervention – Three-year longitudinal findings from the Canadian longitudinal study on aging	17
Basal forebrain global functional connectivity is preserved in asymptomatic presenilin-1 E280A mutation carriers: Results from the Colombia cohort	17
Plasma amyloid-β precursor protein 669–711/amyloid-β1–42 ratio is associated with cognition in Alzheimer's disease	17
Data-Driven Thresholding Statistically Biases ATN Profiling across Cohort Datasets	17
Structural equation modeling confirms interaction of Alzheimer’s disease and vascular disease in hippocampal injury	16
Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry)	16
17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024	16
Editorial Board	16
Serum BDNF and progression to MCI in cognitively normal older adults A prospective cohort study	16
The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry	16
Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study	16
Iron dysregulation in cerebral small vessel disease: A quantitative susceptibility mapping study revealing spatial patterns and cognitive predictive value	16
Corrigendum to “Systematic post-translational modification genome wide identifies therapeutic targets for Alzheimer’s disease: evidence from multi-cohort analysis” [J Prev Alzheimer Dis, 13 (2026) 100	16
Feasibility of computerized motor, cognitive and speech tests in the home: Analysis of TAS Test in 2,300 older adults	16
Interest in and Experience with Genetic Testing for Late-Onset Medical Conditions: Results from the National Poll on Healthy Aging	16
Early detection of Alzheimer’s disease using small RNAs. Results from the EPAD cohort	15
Identifying synergistic combinations of repurposed treatments for Alzheimer’s Disease	15
Brain photobiomodulation: a potential treatment in Alzheimer’s and Parkinson’s diseases	15
Long-term cumulative physical activity associated with less cognitive decline: Evidence from a 16-year cohort study	15
Chinese Preclinical Alzheimer's Disease Study (C-PAS): Design and Challenge from PET Acceptance	15
The differential effect of strength, cognitive and aerobic training combinations on cognitive performance and functional abilities in elderly with cognitive decline: The Fit4Alz project	15
Cardiovascular health, genetic predisposition, and dementia risk among atherosclerotic cardiovascular disease patients	15
Artificial intelligence and the acceleration of Alzheimer’s research - From promise to practice	14
Disclosure of Alzheimer’s disease blood-based biomarker results in a primary care setting: Opportunities and challenges	14
Integrative SMR prioritizes oxidative stress–related regulatory genes for Alzheimer’s disease with brain-tissue validation	14
Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer’s disease	14
Epigenetic aging and blood based neurodegeneration markers in LASI-DAD	14
Tau in Alzheimer's disease: Shaping the future patient journey	14
Virtual reality-based training in patients with alzheimer's disease: A systematic review and meta-analysis	14
Consistency between Treatment Effects on Clinical and Brain Atrophy Outcomes in Alzheimer's Disease Trials	14
Sociodemographic differences in dementia prevention knowledge in Germany: Implications for targeted health communication	14
“Back to Braak”: Role of Nucleus Reuniens and Subcortical Pathways in Alzheimer's Disease Progression	14
Universal Prevention of Dementia in Italy: A Document Analysis of the 21 Italian Regional Prevention Plans	14
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration	14
Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis	14
Editorial Board	14
Association of Preeclampsia with Incident Dementia and Alzheimer's Disease among Women in the Framingham Offspring Study	14
Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study	14
Relationships of Hypnotics with Incident Dementia and Alzheimer's Disease: A Longitudinal Study and Meta-Analysis	14
Association of Multi-Domain Factors with Cognition in the UK Biobank Study	13
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform	13
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force	13
Phenotyping of mild behavioral impairment domains in multi-regional dementia-free older adults of Chinese ethnicity: impulse dyscontrol as the leading domain	13
Add-on combination therapy with monoclonal antibodies: Implications for drug development	13
Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease	13
First Experiences with Amyloid-Related Imaging Abnormalities — Yet without Imaging that Can Rule Out Cerebral Injury or Monitor Efficacy of Recommended Management	13
Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice	13
Fingolimod ameliorates amyloid deposition and neurodegeneration in APP/PS1 mouse model of Alzheimer's disease	13
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease	13
Biomarkers in preclinical and early Alzheimer’s disease in China: a scoping review	13
Polyunsaturated fatty acids, APOE genotypes, and dementia incidence and mortality among hypertensive adults	13
It’s time to address the recruitment bottleneck	13
Alzheimer’s disease prevention by flavonols and their analogs	13
The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort study	12
Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic	12
AI models, bias and data sharing efforts to tackle Alzheimer's disease and related dementias	12
Reducing the Effects of Ageing on Cognition with Therapeutic Intervention of an Oral Multi-Nutrient: The REACTION Pilot Trial Study Design	12
Associations and Potential Multiple Mechanisms between Subjective Hearing Loss and Cognitive Impairment	12
Reply to: Mitochondrial dysfunction as the missing link between circadian syndrome and dementia	12
The role of serum vitamins in mediating the effect of neurodegenerative diseases on subcortical brain volume	12
The Future is Now: Advancing Blood-Based Markers	12
Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer’s Disease: Evidence from the VIVA-MIND trial	12

Response to “Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study”	12
Content	12
Prevalence and co-occurrence of dementia risk factors in Denmark: A nationwide study	12
Left Frontoparietal Control Network Connectivity Moderates the Effect of Amyloid on Cognitive Decline in Preclinical Alzheimer's Disease: The A4 Study	12
Comment on “Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study”	12
Flavonoid-Rich Fruit Intake in Midlife and Late-Life and Associations with Risk of Dementia: The Framingham Heart Study	12
Stress internalization is a top risk for age-associated cognitive decline among older Chinese in the U.S	12
Longitudinal subcortical volume changes and their correlations with multiple PET and fluid biomarkers in dominantly inherited Alzheimer’s disease	12
Embryo Selection for a Carrier of an Early-Onset Alzheimer's Disease-Associated Mutation in the PSEN1 Gene	12
Prevention of Alzheimer's Disease and Cognitive Decline with Diet & Lifestyle: Proceedings of the A. G. Leventis Foundation Conference	12
Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration	12
«Compounded Interest» in Alzheimer's Disease: Do New Amyloid-Targeting Treatments Justify Their Use	12
Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults	12
Association between plant-based diets and incident dementia: results from prospective cohort studies and a meta-analysis	12
Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial	11
Microglial activation states and their implications for Alzheimer's Disease	11
Preventing dementia in Italy: Estimations of modifiable risk factors and public health implications	11
Visual Event-Related Potentials under External Emotional Stimuli as Early Signs for Mild Cognitive Impairment	11
Latent cognitive profiles and their associations with instrumental activities of daily living among older adults without dementia: A United States national cross-sectional study	11
Higher Cognitive Reserve Is Beneficial for Cognitive Performance Via Various Locus Coeruleus Functional Pathways in the Pre-Dementia Stage of Alzheimer's Disease	11
Comparative efficacy of cognitive training modalities in cognitive impairment: A systematic review and network meta-analysis	11
Spatial amyloid–informed multimodal brain age as an early marker of Alzheimer’s-related vulnerability and risk stratification	11
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies	11
Hypertension acts together with Aβ pathology in late-life to promote memory loss	11
Unveiling Potential Biomarkers in Cerebrospinal Fluid for Amyloid Pathological Positivity in Non-Demented Individuals	11
Solving the 'Goldilocks problem' in dementia clinical trials with multimodal AI	11
Alzheimer's Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners	11
Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylat	11
Assessing the causal role of lipid metabolites in Alzheimer's disease: A mendelian randomization study	11
The role for artificial intelligence in identifying combination therapies for Alzheimer’s disease	11
Screening for Alzheimer’s disease in the community using an AI-driven screening platform: design of the PREDICTOM study	11
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients	10
Associations of ischemic heart disease with brain glymphatic MRI indices and risk of Alzheimer's disease	10
Temporal associations of neuropsychiatric symptoms, demographics and amyloid with subsequent tau burden in older adults	10
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial	10
Lifestyle factors and plasma biomarkers of Alzheimer's disease: A narrative review	10
Plasma Aβ42/Aβ40 determined by mass spectrometry is associated with longitudinal changes in amyloid accumulation, brain atrophy, and conversion to mild cognitive impairment due to Alzheimer’s disease	10
ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease P	10
High Intake of Dietary Cholesterol Decreases the Risk of All-Cause Dementia and AD Dementia: A Results from Framingham Offspring Cohort	10
Current status and future directions for the diagnosis and management of mild cognitive impairment in Southeast Asia: A SEACURE consensus paper	10
APOE ε4-related differences in brain structure, function, and connectivity at midlife: A scoping review	10
Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States	10
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease	10
Brain lymphatic drainage pathways, deep cervical lymphatic surgery, and current insights: A systematic review	10
Motor abilities and cognitive performance in Latinos with autosomal dominant Alzheimer's disease	10
Evaluating evidence-based recruitment strategies for Alzheimer’s disease and related dementias clinical trial research: A literature review	10
A novel early imaging biomarker for glymphatic function: Cerebral cortical arterial pulsatility index from 2-Minute phase-contrast MRI	10
Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults	10
Baseline habitual dietary nitrate intake and Alzheimer's Disease related neuroimaging biomarkers in the Australian Imaging, Biomarkers and Lifestyle study of ageing	10
Corrigendum to Enhancing dementia prediction: A 19-year validation of the CAIDE risk score with insulin resistance and APOE ε4 integration in a population-based cohort	10
Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort	10
Implications of Emerging Uses of Genetic Testing for Alzheimer's Disease	10